Mass General Brigham

At 21 years old, Claudia Umanita was preparing for her junior year at the University of Massachusetts Amherst when her life was forever changed by a diagnosis of colon cancer. Claudia had been referred to Massachusetts General Hospital to remove a mass in her colon. During the operation, her doctors discovered the mass was too large to take out. Soon after, her surgeon told her she had colon cancer. “When it turned out to be cancer, my family and I were completely caught off guard,” Claudia says. “That was some crazy news. Just a shock.” During her time at Mass General Brigham Cancer Institute, Claudia was supported by an incredible care team that included her oncologist Aparna Parikh, MD, and surgeon Hiroko Kunitake, MD, MPH. Throughout Claudia's chemotherapy, she managed to continue working as a teaching assistant while taking a full course load and getting straight A's. Today, Claudia’s cancer is in remission thanks to the care she received at Mass General Brigham Cancer Institute, including support through the Center for Young Adult Colorectal Cancer. While she continues to process the emotional and psychological effects of her diagnosis, she is once again looking ahead—this time with a deeper perspective and renewed optimism for the future. http://spklr.io/6045EyWBx

Follow Adam Bennett, MS, LAT, ATC, an athletic trainer from Mass General Brigham, as he joined the Girl's King Philip Hockey team during the Division 2 State Championship. #NATM #NationalAthleticTrainingMonth

Today is #NationalDoctorsDay! Has a Mass General Brigham doctor made a difference in your care? Let us know in the comments!

Talking about bowel movements may be difficult or awkward, but it's important to tell your doctor about any changes you're experiencing. #ColorectalCancerAwarenessMonth Adjoa Anyane-Yeboa, MD MPH

A new experimental therapy is showing early promise for people living with amyotrophic lateral sclerosis (ALS). In a clinical trial led by researchers at Mass General Brigham and Barrow Neurological Institute, the oral therapy PrimeC was found to be safe and well tolerated. PrimeC is designed to target several of the processes that drive the disease, which affects nerve cells and leads to muscle weakness as well as loss of movement. “The importance of following up on potential therapies that can slow the course of ALS is extraordinarily high for patients and families," says study author Merit Cudkowicz, MD, MSc. "We are determined to accelerate the development of therapies for people living with ALS.” http://spklr.io/6041EyRQ3

At Mass General Brigham Cancer Institute, our experts come together to care for all types of cancer, even the most complex and rare cancers. Leaders like Dr. Chan Raut reflect the strength of our unified cancer team, bringing specialists from across disciplines together to determine the best path forward for every patient. We are one team committed to advancing cancer treatment through research-based innovation, teamwork, and an unwavering focus on patients.

For patients with atrial fibrillation (A-fib), the most common cardiac arrhythmia, advanced treatment typically required a trip to Boston, where teams at Mass General Brigham’s academic medical centers performed a procedure to normalize their heart rhythm. Fortunately, that is no longer the case for A-fib patients in communities north of the city. Patients served by Salem Hospital and those in the seacoast communities of southern New Hampshire and Maine near Wentworth-Douglass Hospital now have a much shorter commute. Both hospitals recently launched A-fib ablation programs, bringing advanced cardiac care closer to home for scores of patients while helping to alleviate demand at our capacity-strained academic medical centers.

Andrew Chan, MD, MPH, gastroenterologist at Mass General Brigham Cancer Institute, shares a simple step you can take to help reduce your risk of colorectal cancer.

At Mass General Brigham Cancer Institute, research fuels everything we do. Our unified cancer team leads one of the largest research portfolios in the world, driving breakthroughs in targeted therapies, immunotherapy, advanced radiation, and emerging technologies like AI. We are one team shaping the future of cancer care, not just for today, but for generations to come.

In this video, Kelly McInnis, DO, shares how we're teaming up with Boston Legacy FC as the club's official medical provider and sports medicine partner for the 2026 National Women's Soccer League season. The collaboration is led by Dr. McInnis who will serve as the club’s Chief Medical Officer and Elizabeth Matzkin, MD, who will serve as the Head Orthopaedic Surgeon. Together, Mass General Brigham and Boston Legacy FC are setting a new standard of care in professional women's soccer. Learn more about our Women’s Sports Medicine Program: http://spklr.io/6049EyrgP